Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy

Iris Noyman; Dana Ekstein; Firas Fahoum; Moshe Herskovitz; Ilan Linder; Bruria Ben Zeev; Sara Eyal

doi:10.1111/epi.17212

Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy

Iris Noyman, Dana Ekstein, Firas Fahoum, Moshe Herskovitz, Ilan Linder, Bruria Ben Zeev, Sara Eyal^*

^*Corresponding author for this work

School of Pharmacy

Research output: Contribution to journal › Comment/debate

9 Scopus citations

Abstract

Presented herein are recommendations for use of nirmatrelvir/ritonavir in patients with epilepsy, as issued by the Steering Committee of the Israeli chapter of the International League Against Epilepsy. The recommendations suggest that patients on moderate-to-strong enzyme-inducing antiseizure medications (ASMs) and everolimus should not be treated with nirmatrelvir/ritonavir; rectal diazepam may be used as an alternative to buccal midazolam; doses of ASMs that are cytochrome P450 (CYP3A4) substrates might be adjusted; and patients treated with combinations of nirmatrelvir/ritonavir and ASMs that are CYP3A4 substrates or lamotrigine should be monitored for drug efficacy and adverse drug reactions.

Original language	English
Pages (from-to)	1276-1278
Number of pages	3
Journal	Epilepsia
Volume	63
Issue number	5
DOIs	https://doi.org/10.1111/epi.17212
State	Published - May 2022

Bibliographical note

Publisher Copyright:
© 2022 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.

Keywords

COVID-19
CYP3A4
antiepileptic drugs
antiseizure medications
drug–drug interactions

Access to Document

10.1111/epi.17212

Cite this

@article{8cca6e67135e4bcba039e7c1a05be98c,

title = "Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy",

abstract = "Presented herein are recommendations for use of nirmatrelvir/ritonavir in patients with epilepsy, as issued by the Steering Committee of the Israeli chapter of the International League Against Epilepsy. The recommendations suggest that patients on moderate-to-strong enzyme-inducing antiseizure medications (ASMs) and everolimus should not be treated with nirmatrelvir/ritonavir; rectal diazepam may be used as an alternative to buccal midazolam; doses of ASMs that are cytochrome P450 (CYP3A4) substrates might be adjusted; and patients treated with combinations of nirmatrelvir/ritonavir and ASMs that are CYP3A4 substrates or lamotrigine should be monitored for drug efficacy and adverse drug reactions.",

keywords = "COVID-19, CYP3A4, antiepileptic drugs, antiseizure medications, drug–drug interactions",

author = "Iris Noyman and Dana Ekstein and Firas Fahoum and Moshe Herskovitz and Ilan Linder and {Ben Zeev}, Bruria and Sara Eyal",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.",

year = "2022",

month = may,

doi = "10.1111/epi.17212",

language = "אנגלית",

volume = "63",

pages = "1276--1278",

journal = "Epilepsia",

issn = "0013-9580",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "5",

}

TY - JOUR

T1 - Using nirmatrelvir/ritonavir in patients with epilepsy

T2 - An update from the Israeli chapter of the International League Against Epilepsy

AU - Noyman, Iris

AU - Ekstein, Dana

AU - Fahoum, Firas

AU - Herskovitz, Moshe

AU - Linder, Ilan

AU - Ben Zeev, Bruria

AU - Eyal, Sara

PY - 2022/5

Y1 - 2022/5

N2 - Presented herein are recommendations for use of nirmatrelvir/ritonavir in patients with epilepsy, as issued by the Steering Committee of the Israeli chapter of the International League Against Epilepsy. The recommendations suggest that patients on moderate-to-strong enzyme-inducing antiseizure medications (ASMs) and everolimus should not be treated with nirmatrelvir/ritonavir; rectal diazepam may be used as an alternative to buccal midazolam; doses of ASMs that are cytochrome P450 (CYP3A4) substrates might be adjusted; and patients treated with combinations of nirmatrelvir/ritonavir and ASMs that are CYP3A4 substrates or lamotrigine should be monitored for drug efficacy and adverse drug reactions.

AB - Presented herein are recommendations for use of nirmatrelvir/ritonavir in patients with epilepsy, as issued by the Steering Committee of the Israeli chapter of the International League Against Epilepsy. The recommendations suggest that patients on moderate-to-strong enzyme-inducing antiseizure medications (ASMs) and everolimus should not be treated with nirmatrelvir/ritonavir; rectal diazepam may be used as an alternative to buccal midazolam; doses of ASMs that are cytochrome P450 (CYP3A4) substrates might be adjusted; and patients treated with combinations of nirmatrelvir/ritonavir and ASMs that are CYP3A4 substrates or lamotrigine should be monitored for drug efficacy and adverse drug reactions.

KW - COVID-19

KW - CYP3A4

KW - antiepileptic drugs

KW - antiseizure medications

KW - drug–drug interactions

UR - http://www.scopus.com/inward/record.url?scp=85126030107&partnerID=8YFLogxK

U2 - 10.1111/epi.17212

DO - 10.1111/epi.17212

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 35239193

AN - SCOPUS:85126030107

SN - 0013-9580

VL - 63

SP - 1276

EP - 1278

JO - Epilepsia

JF - Epilepsia

IS - 5

ER -

Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this